Human plasma kallikrein inhibitors
AssigneeBioCryst Pharmaceuticals, Inc.
InventorsPravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
Claims45
A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
Dependencies are inferred from the claim text.